Sharemaestro company-news research for Nxera Pharma Co., Ltd. (4565), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
JPX
Japan
Insufficient evidence
Company news sentiment
Latest 4565 news and sentiment
Nxera Pharma Co., Ltd.
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score50Neutral is 50
No directional headline signal
0/100 evidence confidence
0% direct company focus
2 current stories across 0 publishers
Current company news
No current company-news score
No company-specific headline in the last 30 days currently passes the date and relevance checks. The displayed 50 means no score, not a neutral view.
Observed headline tone50/100
→
Published 30-day score50/100
Latest source headline
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress
finance.yahoo.com · 03 Sep 2026 06:34
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
Available information
2 current stories are mapped specifically to 4565.
Why there is no score
The stories agree, but freshness-weighted evidence is only 0.000.
Confidence is 0/100, below the threshold for a firm score.
50/100
News scoreNo directional headline signal
0/100
Confidencethin evidence
0%/100
Company news2 company stories
100/100
Story agreement0/100 difference
News history
Daily score and story count over 30 days
24 Aug08 Sep22 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.0 after freshness weightingSource breadth0
0 independent publishersCompany relevance0
share tied directly to this companyFreshness1
recency-weighted evidenceAgreement100
how closely stories agreePublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
No sufficiently fresh, directly relevant company news is available for a price comparison.
26 completed price weeks13 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
27 Mar23 Jun18 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
18 Sep 202650JPY 1299.0+7.9%
11 Sep 202650JPY 1204.0+5.6%
04 Sep 202650JPY 1140.0+1.6%
28 Aug 202650JPY 1122.0+1.7%
21 Aug 202650JPY 1103.0-0.2%
14 Aug 202650JPY 1105.0+27.7%
07 Aug 202650JPY 865.0-1.3%
31 Jul 202650JPY 876.0-3.0%
Insufficient evidence
News subjects
What is shaping the score
Market update501 stories · 50%
Regulatory and legal501 stories · 50%
Source mix
Where the evidence comes from
finance.yahoo.com502 stories · 100%
Recurring subjects
Subjects appearing most often
Clinical Trials2Biotech2Pharma1M A1Fda Approval1Alzheimers1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
22 Jun50 neutral22 Sep 07:20
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 22 Sep 07:20 | 50 | +0 | 0/100 (0) | 2 (-2) | Insufficient |
| 03 Sep 23:59 | 50 | +0 | 0/100 (0) | 4 (0) | Insufficient |
| 26 Aug 23:59 | 50 | +0 | 0/100 (0) | 4 (-1) | Insufficient |
| 07 Aug 23:59 | 50 | +0 | 0/100 (0) | 5 (+1) | Insufficient |
| 06 Aug 23:59 | 50 | +0 | 0/100 (0) | 4 (+1) | Insufficient |
| 31 Jul 23:59 | 50 | +0 | 0/100 (0) | 3 (-2) | Insufficient |
| 12 Jul 23:59 | 50 | +0 | 0/100 (0) | 5 (+1) | Insufficient |
| 10 Jul 23:59 | 50 | +0 | 0/100 (0) | 4 (+1) | Insufficient |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#1—Not directional
finance.yahoo.comDirect company coverageStored article
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress
Nxera Pharma Tokyo, Japan and Cambridge, UK, 3 September 2026 – Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that Centessa Pharmaceuticals Limited ("Centessa"), a wholly-owned subsidiary of Eli Lilly and Company ("Lilly"), has achieved a late-stage development milestone associated with its selective orexin receptor 2 (OX2R) agonist portfolio. This milestone triggers a payment of US$8.6 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the third quarter of the fiscal year ending 31 Decembe
BiotechClinical TrialsM APharma
- Published
- 03 Sep 2026 06:34
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.7d old
- Duplicates
- 1 consolidated
#2—Not directional
finance.yahoo.comDirect company coverageStored article
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
Nxera Pharma NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with Neurocrine Nxera to receive a US$10 million milestone payment upon IND Acceptance, as part of the overall milestone package Nxera retains development and commercialization rights to the M1 receptor agonist for all indications in Japan Tokyo, Japan and Cambridge, UK, 26 August 2026 – Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) announces that its partner Neurocrine Bioscience
AlzheimersBiotechClinical TrialsFda Approval
- Published
- 26 Aug 2026 07:33
- News subject
- Regulatory and legal
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 25.7d old
- Duplicates
- 1 consolidated
Earlier company news
4565 news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 8 older 4565 headlines. Open one page at a time when you need them.
Open older archiveHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.